Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 19

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 19
---
 Stock by Selling Stockholders could cause the price of our Common                                           
 Stock to fall and the issuance and sale of Common Stock upon exercise of warrants by Selling Stockholders will cause dilution. The           
 issuance of our Common Stock by the Company in the Primary Offering and upon exercise of our outstanding warrants in this Offering           
 will cause immediate and substantial dilution.                                                                                               |
| ● | Article VIII of our Bylaws designates the appropriate state or federal court in Nevada as the sole                                           
 and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, and therefore may limit          
 our shareholders’ ability to choose a forum for disputes with us or our directors, officers, employees, or agents                            |
| ● | Nevada law and provisions in our Articles of Incorporation and our new Nevada bylaws could make a                                            
 merger, tender offer or proxy contest difficult, thereby depressing the market price of our Common Stock.                                    |
| ● | We may be subject to securities litigation, which is expensive and could divert management attention.                                        |
| ● | FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock.                                               |
| ● | State securities laws may limit secondary trading, which may restrict the states in which you can                                            
 sell the shares purchased in this Offering.                                                                                                  |

<div align='center'>8

RISK FACTORS</div>

Investing in our Common Stock involves a high degree of risk. Before investing in our Common Stock, you should carefully consider the risks described below, as well as the other information in this Prospectus, including our consolidated financial statements and the related notes. In addition, we may face additional risks and uncertainties not currently known to us, or which as of the date of this registration statement we might not consider significant, which may adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could be materially adversely affected. In such a case, the trading price of our Common Stock could decline due to any of these risks or uncertainties, and you may lose part or all of your investment.

Risks Related to our Business and Financial Condition

We have a history of losses and may never achieve profitability.

We are a development-stage biopharmaceutical
company and have incurred significant losses since inception. We expect to continue incurring operating losses for the foreseeable future
and we anticipate that we will incur operating losses and negative cash flow in the foreseeable future. We have not yet commercialized
any products and cannot be sure